DividendMapper
Sensient Technologies Corporation logo

SXT

Sensient Technologies Corporation

  • Basic Materials
  • US companies in Chemicals - Specialty (24)
  • NYSE · USD
  • Mkt cap $5.6bn

$131.53

as of 29 Oct 2026, 5% below its 52-week high

Screens as reasonably placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield
1.25%Last 12 months of regular payments at today's price
Forward yield
1.25%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover
2.3×Pays 44% of earnings
Cash cover
0.1×Free cash flow over dividends paid
5y dividend growth
+1.0% a yearNo cut since FY2008
Next ex-dividend date
Estimated10 Nov 2026Quarterly dividend of about $0.41

Compared with US companies in Chemicals - Specialty (24)

  • Trailing yield is lower than 16 of the 23 other US companies in Chemicals - Specialty.
  • 5y dividend growth (as paid) is lower than 19 of the 21 other US companies in Chemicals - Specialty with a 5y growth figure.

Quality

50

Moderate

Capacity to keep growing the dividend

Risk

25

Low

Signals of dividend-cut pressure

Trim

68

Moderate

How extended the valuation looks

Why Quality is 50

SXT against US companies in Chemicals - Specialty (24)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of SXT’s past readings.

  • P/E33.0×P81, poor for this measure
  • Yield1.33%P0, poor for this measure
  • FCF payout1556.9%P100, poor for this measure
  • Net debt / EBITDA2.43P22, good for this measure
  • DGR 5y+1.0%P6, poor for this measure
  • ROIC8.9%P53, neutral for this measure
Open valuation history

Forecast your income with the SXT dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.